Rezolute (RZLT)
NASDAQ:RZLT
Want to see RZLT full AI Analyst Report?
Top Page
Rezolute
(NASDAQ:RZLT)
Select Model
Select Model
Rating:50Neutral
Price Target:
$3.50
▲(1.16% Upside)
Action:ReiteratedDate:04/09/26
The score is primarily held back by weak financial performance driven by zero revenue, widening losses, and heavy cash burn. Technicals provide only a modest offset via short-term momentum, while valuation remains unfavorable/unclear given negative earnings and no dividend.
Positive Factors
Low Leverage / Strong Balance Sheet
Very low debt and sizable assets provide lasting financial flexibility for a clinical-stage biotech. This reduces near-term insolvency risk, supports continued R&D spending and trial execution over the next 2–6 months, and lowers the chance of forced asset sales or distressed financing events.
Negative Factors
Pre-revenue / Widening Losses
Being pre-revenue with materially widening losses is a persistent weakness: without commercial sales the firm remains dependent on financing to sustain operations. Continued negative returns erode equity value and limit reinvestment options absent clinical success or new funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Strong Balance Sheet
Very low debt and sizable assets provide lasting financial flexibility for a clinical-stage biotech. This reduces near-term insolvency risk, supports continued R&D spending and trial execution over the next 2–6 months, and lowers the chance of forced asset sales or distressed financing events.
Read all positive factors
Rezolute (RZLT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$343.55M
Dividend YieldN/A
Average Volume (3M)2.74M
Price to Earnings (P/E)―
Beta (1Y)1.13
Revenue GrowthN/A
EPS Growth26.65%
CountryUS
Employees64
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.22
Shares Outstanding95,697,685
10 Day Avg. Volume1,456,794
30 Day Avg. Volume2,744,138
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.09
Price to Sales (P/S)0.00
P/FCF Ratio-4.91
Enterprise Value/Market Cap0.91
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-20.79K
Enterprise Value/Ebitda-3.54
Forecast
1Y Price Target
$5.00Price Target Upside44.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.76
Revenue Forecast (FY)N/A
Rezolute Business Overview & Revenue Model
Company Description
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal ...
How the Company Makes Money
Rezolute does not have a broadly disclosed, established commercial revenue stream from marketed products; as a clinical-stage biotech, its operations are primarily funded through external financing rather than recurring product revenue. Primary so...
Rezolute Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
68
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -15.00K | 0.00 | 0.00 | 0.00 | 0.00 | -13.00K |
| EBITDA | -88.21M | -79.86M | -70.39M | -55.96M | -39.24M | -20.51M |
| Net Income | -84.23M | -74.41M | -68.46M | -51.79M | -41.06M | -20.90M |
Balance Sheet | ||||||
| Total Assets | 138.63M | 175.49M | 132.74M | 123.72M | 152.42M | 42.61M |
| Cash, Cash Equivalents and Short-Term Investments | 132.94M | 167.86M | 126.87M | 101.90M | 150.41M | 41.05M |
| Total Debt | 1.28M | 1.61M | 2.23M | 2.48M | 188.00K | 14.42M |
| Total Liabilities | 10.63M | 13.36M | 11.73M | 7.55M | 2.95M | 16.51M |
| Stockholders Equity | 128.00M | 162.13M | 121.00M | 116.17M | 149.47M | 26.10M |
Cash Flow | ||||||
| Free Cash Flow | -77.15M | -69.08M | -57.37M | -44.63M | -39.62M | -20.44M |
| Operating Cash Flow | -77.15M | -69.08M | -57.37M | -44.48M | -39.62M | -20.44M |
| Investing Cash Flow | -22.28M | -14.54M | 48.70M | -101.46M | 0.00 | 0.00 |
| Financing Cash Flow | 102.44M | 107.33M | 63.03M | 11.57M | 148.98M | 51.53M |
Rezolute Technical Analysis
Neutral
3.46
Price Trends
3.18
Positive
3.81
Negative
5.74
Negative
Market Momentum
0.15
Negative
56.53
Neutral
58.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RZLT, the sentiment is Neutral. The current price of 3.46 is above the 20-day moving average (MA) of 3.22, above the 50-day MA of 3.18, and below the 200-day MA of 5.74, indicating a neutral trend. The MACD of 0.15 indicates Negative momentum. The RSI at 56.53 is Neutral, neither overbought nor oversold. The STOCH value of 58.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for RZLT.
Rezolute Risk Analysis
Rezolute disclosed 31 risk factors in its most recent earnings report. Rezolute reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Rezolute Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $2.60B | -6.47 | -246.19% | ― | ― | -12.93% | |
59 Neutral | $1.72B | -16.13 | -56.64% | ― | -36.36% | -945.72% | |
54 Neutral | $1.08B | -10.26 | -34.23% | ― | 522.13% | 62.68% | |
53 Neutral | $875.74M | -27.51 | -42.39% | ― | 116.64% | 47.93% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $343.55M | -2.69 | -64.81% | ― | ― | 26.65% | |
43 Neutral | $917.47M | -42.71 | -14.58% | ― | 38.16% | 48.43% |
* Healthcare Sector Average
RZLT
Rezolute
3.37
0.23
7.32%
GERN
Geron
1.56
0.21
15.56%
ABUS
Arbutus Biopharma
4.60
1.39
43.30%
XNCR
Xencor
12.80
2.20
20.75%
KOD
Kodiak Sciences
46.44
43.19
1328.92%
TSHA
Taysha Gene Therapies
6.46
5.01
345.52%
Rezolute Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
Rezolute Prepares FDA Submission After sunRIZE Trial Review
Neutral
Mar 24, 2026
On March 24, 2026, Rezolute reported outcomes from a March 17 in-person Type B FDA meeting regarding sunRIZE, its Phase 3 trial of ersodetug in congenital hyperinsulinism, after the study previously failed to meet its primary endpoint in December ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.